Launched in 2017, the EBC-led Value of Treatment (VOT) for Brain Disorders in Europe is a health economics & outcomes research project addressing the burden of brain disorders.
A first analysis of 9 neurological and mental disorders was conducted and released in 2017. Two years later, a second round on new therapeutic areas was launched, focusing on rare diseases (Ataxia, Dystonia and Phenylketonuria) and mental disorders (Anorexia Nervosa, Autism Spectrum Disorder, Major Depressive Disorder). This second round allowed to dig deeper into the current unmet needs in health care using a value-based approach.
On 8 June 2021, case study working groups present a synthesis of their VOT 2 research project results and examine the most critical issues in rare diseases and mental disorders from different perspectives, including policymakers, innovators, academia and industry, medical professionals and patient organisations.